M.D. Anderson Cancer Center: Lymphoma, Non-Hodgkin trials

The registry lists 36 Lymphoma, Non-Hodgkin studies with M.D. Anderson Cancer Center as lead sponsor. 3 are open to participants now and 19 have results posted.

Phase 1 12Phase 2 25Phase 3 2No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) PatientsRecruitingNCT05529069Phase 2
• Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell TherapyRecruitingNCT04870853
• Personalized NK Cell Therapy in CBTRecruitingNCT02727803Phase 2
• Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT03210662Phase 2Results posted
• Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid MalignanciesCompletedNCT03056339Phase 1/2Results posted
• Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's LymphomaCompletedNCT03019640Phase 2Results posted
• Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaTerminatedNCT02420795Phase 1/2Results posted
• Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaTerminatedNCT02419469Phase 2Results posted
• Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid MalignanciesCompletedNCT01919619Phase 2Results posted
• Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin LymphomaCompletedNCT01701986Phase 1/2Results posted
• Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine ConditioningCompletedNCT01572662Phase 2Results posted
• Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's LymphomasCompletedNCT01329900Phase 2Results posted
• Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic LymphomaCompletedNCT00866749Phase 2Results posted
• Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's LymphomaTerminatedNCT00810576Phase 2Results posted
• SAHA + CHOP in Untreated T-cell Non-Hodgkin's LymphomaCompletedNCT00787527Phase 1/2Results posted
• Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin LymphomaCompletedNCT00695786Phase 2Results posted
• Radioimmunotherapy With 90Y Zevalin for Orbital LymphomaCompletedNCT00387023Not applicableResults posted
• Effect of Zoledronic Acid on Chemotherapy Induced Bone LossCompletedNCT00352846Phase 3Results posted
• Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's LymphomaCompletedNCT00299182Phase 1/2Results posted
• Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or YoungerCompletedNCT00290498Phase 2Results posted
• Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's LymphomaCompletedNCT00081861Phase 2Results posted
• Randomized Double Cord Blood Transplant StudyCompletedNCT00067002Phase 2Results posted
• Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin LymphomaWithdrawnNCT04220008Phase 2
• Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or LymphomaWithdrawnNCT04029038Phase 1/2
• Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell TransplantActive, not recruitingNCT03622788Phase 1/2
• CD19-Specific T Cells Post AlloSCTTerminatedNCT03579888Phase 1
• Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell LymphomasWithdrawnNCT03205891Phase 1
• Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell TransplantActive, not recruitingNCT02861417Phase 2
• Infusion of Allogeneic, 3rd Party CD19-specific T CellsWithdrawnNCT02274506Phase 1
• NK Cells in Cord Blood TransplantationStatus unknownNCT01619761Phase 1
• Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell LymphomaCompletedNCT01590732Phase 1
• Rituximab Maintenance After Autologous TransplantationTerminatedNCT01103388Phase 3
• Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid MalignanciesTerminatedNCT00038883Not applicable
• Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure StatesTerminatedNCT00038779Not applicable
• A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's LymphomaCompletedNCT00038545Phase 2
• Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's LymphomaCompletedNCT00003245Phase 2